Merz's Novabel Suspended In EU, Pausing New Business Strategy
This article was originally published in The Gray Sheet
Executive Summary
U.K authorities told health care professionals and aesthetic practitioners on August 12 not to use Merz Pharmaceuticals' dermal filler Novabel (alginate) because of a potential association with skin nodules and induration, particularly in the infra-orbital area, and to return all unused product to the company
You may also be interested in...
Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition
Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.